Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors

Rachana Shah
Gregory J. Matthews
Rhia Y. Shah
Catherine McLaughlin
Jing Chen
Dominic S. Raj, George Washington UniversityFollow
et al.

Document Type

Journal Article

Publication Date

8-2015

Journal

American Journal of Kidney Diseases

Volume

66

Issue

2

Inclusive Pages

266-273

DOI

10.1053/j.ajkd.2015.01.021

Keywords

Cardiovascular Diseases--blood; Chemokine CX3CL1--blood; Diabetes Mellitus--blood; Metabolic Syndrome X--blood; Myocardial Infarction--blood; Renal Insufficiency, Chronic--blood

APA Citation

Shah, R., Matthews, G. J., Shah, R. Y., McLaughlin, C., Chen, J., Wolman, M., . . . Rahman, M. (2015). Serum fractalkine (CX3CL1) and cardiovascular outcomes and diabetes: Findings from the chronic renal insufficiency cohort (CRIC) study. American Journal of Kidney Diseases, ;66(2):266-73. doi: 10.1053/j.ajkd.2015.01.021

Peer Reviewed

1